title: [Treatment of non-small cell lung cancer - where we are?].
abstract: Lung cancer is the most common cancer in Poland and in the world, unfortunately diagnosed too late, and combined with  a very poor prognosis. For most patients with NSCLC the only possibility of treatment is palliative therapy, including  chemotherapy and, in the recent years, molecular targeted therapy. In first-line treatment, cisplatine-based "doublets" are  most effective, and in second-line, pemetreksed and docetaxel are used. Recently, maintenance chemotherapy has been  introduced.  Although standard chemotherapy improves the quality of life in the patients with advanced NSCLC, due to significant toxicity  such treatment should be applied only in patients in good performance status.  The introduction of targeted therapy, based on the molecular profile of the patient has allowed the management to be  personalized, which may result in more effective treatment and may be safer for the patient.
authors.affiliation: Katedra i Klinika Pneumonologii, Onkologii i Alergologii Uniwersytetu Medycznego w Lublinie. janusz.milanowski@umlub.pl
authors.forename: Janusz
authors.initials: J
authors.lastname: Milanowski
authors.forename: Katarzyna
authors.initials: K
authors.lastname: Szmygin-Milanowska
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D018572:Disease-Free Survival; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000523:psychology; D011044:Poland; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents